Fears of a wintertime "tripledemic" have prompted warnings to get flu shots and reformulated COVID boosters — but there are no such options for the third pathogen in circulation: respiratory syncytial virus, or RSV. That could soon change.
Driving the news: Pfizer on Tuesday announced promising topline results of a late-stage clinical trial for an experimental RSV vaccine. The vaccine would offer protection to infants from birth by vaccinating women while they're still pregnant.
